A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

Vitiligo Clinical Trial

Official title:

An Open Label, Phase II Study to Assess the Changes in Pigmentation and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants in the Treatment of Vitiligo on the Face

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05210582
• Other study ID #: CUV104
• Status: Recruiting
• Phase: Phase 2
• Start date: October 11, 2022
• Est. completion date: August 2023

Study information

• Verified date: February 2023
• Source: Clinuvel Pharmaceuticals Limited
• Contact: Head of Clinical Operations
• Phone: +441372860765
• Email: mail[@]clinuvel.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6
• Est. completion date: August 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female patients with a confirmed diagnosis of vitiligo on the face and with T-VASI range 0.5-50%

• Stable face vitiligo with F-VASI of at least 0.1%

• Stable or slowly progressive vitiligo over a 3-month period

• Fitzpatrick skin types IV-VI

• Treatment with narrowband (NB)-UVB light 2-3 times per week during the last four weeks preceding the first implant for priming

Exclusion Criteria:

• Patients with segmental vitiligo

• Fitzpatrick skin types I-III

• Treatment with NB-UVB phototherapy in the last three months prior to phototherapy, excluding the sessions for priming in the four weeks prior to treatment. A 3-month washout period from phototherapy is necessary prior to priming.

• Previous topical treatment for vitiligo

• Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant

• History of melanoma or lentigo maligna

• Any current skin disease that may interfere with the study evaluation

• Presence of severe hepatic disease or hepatic impairment

• Renal impairment

• History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation

• Female who is pregnant or lactating

• Female of child-bearing potential not using adequate contraceptive measures during the treatment phase and for a period of three months thereafter

• Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures, as described above

• Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit

• Use of any other prior and concomitant therapy which may interfere with the objective of the study

• Subjects assessed as not suitable for the study in the opinion of the Investigator

Related Conditions & MeSH terms

• Vitiligo

Intervention

Drug:
• Afamelanotide
Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.

Locations

Country	Name	City	State
United States	CLINUVEL Investigational site	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Clinuvel, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on facial lesions	Measured using Vitiligo Area Scoring Index (VASI). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100)	From Baseline to Day 84
Secondary	Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on body surface area	Proportion of participants achieving VASI25 on body surface area (excluding hands and feet). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100).	From Baseline to Day 84
Secondary	Percentage change in pigmentation on body surface area measured by the VASI scoring system	Percentage change in pigmentation on body surface area (excluding hands and feet) measured by VASI scoring system. A decrease in VASI indicates a reduction of the body surface area affected by vitiligo (possible range 1-100)	From Baseline to Day 84
Secondary	Percentage change in pigmentation on facial surface area measured by the VASI scoring system	A decreased VASI indicates a reduction in the faces' degree of depigmentation (possible range 1-100)	From Baseline to Day 168
Secondary	Change in Perception of Vitiligo Severity using a vitiligo validated specific tool (A)	The higher the score, the more severe the disease	From Baseline to Day 168
Secondary	Change in Noticeability of Vitiligo using a vitiligo validated specific tool (B)	Higher the value means lower noticeability	From Baseline to Day 168
Secondary	Change in Quality of life using a vitiligo specific tool (C)	Higher value means a lower quality of life	From Baseline to Day 168